Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Marcel van Gelderen"'
Autor:
Marcel van Gelderen, John Meijer, Cees Korstanje, Christiane Collins, Matthias Stölzel, Virginie Kerbusch
Publikováno v:
The Journal of Clinical Pharmacology. 57:1534-1544
To explore the role of β1-adrenoceptors (ARs) in the heart rate response to the selective β3-adrenoceptor agonist mirabegron, 12 young male volunteers received single oral doses of the nonselective β1/2-AR antagonist propranolol (160 mg), the sele
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7db4e743cbfa2e9d8bd9538ec4e51e2b
https://doi.org/10.1002/jcph.952
https://doi.org/10.1002/jcph.952
Publikováno v:
Clinical Therapeutics. 37:1031-1044
Purpose The objective of these studies was to evaluate the pharmacokinetic profile, safety, and tolerability of mirabegron, a β 3 -adrenoceptor agonist for the treatment of overactive bladder, including food effects (low- or high-fat meals) and sex,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e95fbc0d292bcec7c3cb446b5003ce1
https://doi.org/10.1016/j.clinthera.2015.02.021
https://doi.org/10.1016/j.clinthera.2015.02.021
Publikováno v:
Journal of Electrocardiology. 47:856-862
Background Detection of food-induced QTc shortening has been proposed as an assay sensitivity in thorough QT/QTc (TQT) studies. Data of a large clinical study were used to investigate the food effects on QTc intervals. Methods Day-time drug-free 12-l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd15fdc8dc3ff03b9bf457eb8e193377
https://doi.org/10.1016/j.jelectrocard.2014.07.026
https://doi.org/10.1016/j.jelectrocard.2014.07.026
Publikováno v:
Journal of Cardiovascular Electrophysiology. 25:1232-1241
E14-Compatible Holter Bin and QTcI Introduction The Holter bin method evaluates QT interval changes in the presence of heart rate changes without correcting the QT interval. However, the method does not allow time-matched comparisons, thus contradict
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::63420af19a76aafa9613e3bf5adf2baa
https://doi.org/10.1111/jce.12450
https://doi.org/10.1111/jce.12450
Autor:
Reiner Tretter, E. Marcel van Gelderen, John Meijer, Walter Krauwinkel, Gregory Strabach, Virginie Kerbusch
Publikováno v:
Clinical Pharmacology in Drug Development. 2:255-263
Mirabegron, a selective β3-adrenoceptor agonist, is approved for the treatment of overactive bladder (OAB). Solifenacin is a muscarinic receptor antagonist widely used in the treatment of OAB. This open-label, 1-sequence, 2-arm study investigated wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b54f125c0101eb41b076bbcc5bc3214c
https://doi.org/10.1002/cpdd.37
https://doi.org/10.1002/cpdd.37
Autor:
Virginie Kerbusch, Walter Krauwinkel, Selina Moy, Alan Marion, Donna Kowalski, Michael Roy, James Keirns, Taiji Sawamoto, Jennifer Lee, Marcel van Gelderen, John Meijer, Shin Takusagawa
Publikováno v:
Clinical Drug Investigation. 33:429-440
Mirabegron is a β3-adrenoceptor agonist for the treatment of overactive bladder. There has been little information published or presented about the involvement of cytochrome P450 (CYP) isoenzymes 3A and 2D6 in the metabolism of mirabegron in humans;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e77f60f4009cebac2dbca806031d271
https://doi.org/10.1007/s40261-013-0084-y
https://doi.org/10.1007/s40261-013-0084-y
Autor:
Marcel van Gelderen, Taiji Sawamoto, Jennifer Lee, Virginie Kerbusch, Nicole Grunenberg, Wenhui Zhang, Donna Kowalski, Selina Moy, James Keirns
Publikováno v:
Clinical Therapeutics. 35:333-341
Background Mirabegron is a β3-adrenoceptor agonist used for the treatment of overactive bladder. Mirabegron is formulated as an extended-release tablet using oral controlled-absorption system (OCAS) technology. Objective This study was designed to a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::862d9a65e57be577ff27fe8b26fd46bd
https://doi.org/10.1016/j.clinthera.2013.02.014
https://doi.org/10.1016/j.clinthera.2013.02.014
Autor:
John Meijer, Wenhui Zhang, Virginie Kerbusch, Jan van Dijk, Walter Krauwinkel, Marcel van Gelderen, Reiner Tretter, Monique Groen-Wijnberg
Publikováno v:
European journal of drug metabolism and pharmacokinetics. 42(3)
Mirabeg ron is a selective β3-adrenoceptor agonist approved for the treatment of overactive bladder (OAB). Four phase 1 studies were conducted in healthy subjects to evaluate the potential for pharmacokinetic interactions between mirabegron and metf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e0d515dde0d10f7b42cff0b46d325fd
https://pubmed.ncbi.nlm.nih.gov/27350625
https://pubmed.ncbi.nlm.nih.gov/27350625
Autor:
Marloes Schaddelee, Sjoerd van Marle, Hiromi Iitsuka, Nicole Grunenberg, Donna Kowalski, Marcel van Gelderen, John Meijer, Jennifer Lee, Charlotte Eltink, Virginie Kerbusch, Taiji Sawamoto, Hiroshi Matsushima, Ted Drogendijk, Wenhui Zhang, Selina Moy
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 50:838-850
Background and objectives Mirabegron is a potent and selective β3-adrenoceptor agonist in development for treatment of overactive bladder. Methods Mirabegron pharmacokinetics after single intravenous (i.v.) and oral doses, absolute bioavailability (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4444d0959535027ce74c069c16ca926e
https://doi.org/10.5414/cp201782
https://doi.org/10.5414/cp201782
Publikováno v:
Journal of Electrocardiology. 45:571-581
Objective A statistical modelling study investigated whether incorporating the curvatures of QT/RR patterns into the individual-specific QT heart rate correction increases QTc data accuracy. Methods Repeated ECG readings were available from 4 differe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af198f65231373ce578aee761fc63f46
https://doi.org/10.1016/j.jelectrocard.2012.07.017
https://doi.org/10.1016/j.jelectrocard.2012.07.017